Blau Farmacêutica S.A. logo

Blau Farmacêutica S.A. (BLAU3)

Market Closed
4 Dec, 19:55
B3 B3
R$
13. 48
+0.08
+0.6%
R$
2.78B Market Cap
- P/E Ratio
0.34% Div Yield
421,700 Volume
- Eps
R$ 13.4
Previous Close
Day Range
13.4 13.71
Year Range
11.48 14.76
Want to track BLAU3 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BLAU3 closed today higher at R$13.48, an increase of 0.6% from yesterday's close, completing a monthly increase of 0.6% or R$0.08. Over the past 12 months, BLAU3 stock gained 3.93%.
BLAU3 pays dividends to its shareholders, with the most recent payment made on Oct 03, 2025. The next announced payment will be in In 1 weeks on Dec 16, 2025 for a total of R$0.11256.
The last earnings report, released on Nov 04, 2025, exceeded the consensus estimates by 0.28%. On average, the company has surpassed earnings expectations by 0.14%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on B3 (BRL).

BLAU3 Chart

Blau Farmacêutica S.A. (BLAU3) FAQ

What is the stock price today?

The current price is R$13.48.

On which exchange is it traded?

Blau Farmacêutica S.A. is listed on B3.

What is its stock symbol?

The ticker symbol is BLAU3.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.34%.

What is its market cap?

As of today, the market cap is 2.78B.

Has Blau Farmacêutica S.A. ever had a stock split?

No, there has never been a stock split.

Blau Farmacêutica S.A. Profile

- Industry
- Sector
Mr. Marcelo Rodolfo Hahn CEO
B3 Exchange
- ISIN
Brazil Country
1,900 Employees
5 Dec 2025 Last Dividend
- Last Split
- IPO Date

Overview

Blau Farmacêutica S.A. is a discerning player in the pharmaceutical industry, demonstrating a robust presence across multiple Latin American countries, including Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and even extending its reach into the United States. Founded in 1987 and with its headquarters stationed in Cotia, Brazil, the company predominantly focuses on the development, production, and distribution of high-complexity drugs. The diverse range of medications that it offers caters to a wide array of health segments such as immunology, hematology, oncology, nephrology, infectious diseases, anesthesiology, and more, illustrating the company's commitment to addressing a plethora of medical needs. Catering to an extensive clientele, Blau Farmacêutica ensures that its products are accessible to a variety of healthcare facilities, including hospitals, private clinics, chemotherapy and hemodialysis centers, as well as public health institutions, thereby facilitating comprehensive patient care.

Products and Services

  • Uterine Stimulator: A medication designed for the enhancement of uterine contractions, aiding in various gynecological and obstetric procedures.
  • Anesthetics: Compounds primarily utilized to induce anesthesia, ensuring pain-free surgical and diagnostic procedures.
  • Feminine Healthcare: A range of products focused on addressing health issues exclusive to women, promoting wellness and prevention.
  • Oncological Products: Specialized medications for the treatment of various types of cancer, supporting efforts in oncology care.
  • Antivirals and Antiretrovirals: These medications are aimed at combating viral infections, including those caused by HIV, thereby playing a critical role in infectious disease management.
  • Acid Pump Inhibitor: Designed to reduce stomach acid production, these drugs are essential for treating conditions like gastroesophageal reflux disease (GERD).
  • Antithrombotic: Medications that help prevent blood clots, critical in the management of cardiovascular conditions and in preventing thrombotic events.
  • Antirheumatic: Drugs used in the treatment of rheumatic diseases, aiming to reduce inflammation and alleviate pain.
  • Antibiotics: A broad category of drugs targeting bacterial infections, essential in both acute care and ongoing disease management.
  • Biopharmaceuticals: These encompass a wide range of products including proteins, nucleic acids used for therapeutic or in vivo diagnostic purposes, and are produced biologically.
  • Biosimilars: Medications that are highly similar to, and have no clinically meaningful differences from an existing approved reference biologic drug, offering more accessible treatment options.
  • Hemoderivatives: Products derived from human blood, used in various treatments including those for immune system conditions and coagulation disorders.
  • Thrombolytics: Drugs that dissolve blood clots, significantly used in acute cardiovascular emergencies like myocardial infarction.
  • Biological Drugs: This includes a broad category of products that are produced using living organisms or contain components of living organisms.
  • Oral and Injectable Drugs for Treating Cancer: These products provide multiple administration options for cancer treatment, catering to patient-specific needs.
  • Specialized Treatments for Infectious Diseases: Tailored therapies designed to fight specific infectious diseases, supporting targeted treatment strategies.
  • Prescription and Non-prescription Drugs: A wide range of medicinal products addressing various health conditions, available with or without a doctor's prescription.
  • Dermo-medicines, Condoms, and Others: These products cater to dermatological health, sexual health, and other areas, for both retail and non-retail markets.
  • Blood Products, Biological, Biotechnological, and Antiretroviral Drugs: These are critical in treating a variety of conditions, from blood disorders to HIV/AIDS, showcasing the company's innovative approach to medicine.

Contact Information

Address: Rodovia Raposo Tavares,
Phone: 55 11 4615 9400